Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer

Rein,Daniel  T.; Volkmer,Anne   Kathrin; Volkmer,Jens; Beyer,Ines  M.; Janni,Wolfgang; Fleisch,Markus  C.; Welter,Anne   Kathrin; Bauerschlag,Dirk; Schöndorf,Thomas; Breidenbach,Martina

doi:10.3892/ol.2012.553

Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer

Authors:
- Daniel T. Rein
- Anne Kathrin Volkmer
- Jens Volkmer
- Ines M. Beyer
- Wolfgang Janni
- Markus C. Fleisch
- Anne Kathrin Welter
- Dirk Bauerschlag
- Thomas Schöndorf
- Martina Breidenbach
View Affiliations

Affiliations: Department of Obstetrics and Gynaecology, University of Düsseldorf Medical Centre, D-40225 Düsseldorf, Germany, Department of Urology, University of Düsseldorf Medical Centre, D-40225 Düsseldorf, Germany, Department of Obstetrics and Gynaecology, Rhine-Westphalian Technical University, D-52074 Aachen, Germany, Institute for Clinical Research and Development, D-55116 Mainz, Germany
Published online on: January 3, 2012 https://doi.org/10.3892/ol.2012.553
Pages: 530-534

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer patients often suffer from malignant ascites and pleural effusion. Apart from worsening the outcome, this condition frequently impairs the quality of life in patients who are already distressed by ovarian cancer. This study investigated whether single intraperitoneal administration of the anti-VEGF antibody bevacizumab is capable of reducing the ascites‑related body surface and prolonging survival. The study was performed in an orthotopic murine model of peritoneal disseminated platin-resistant ovarian cancer. Mice were treated with bevacizumab and/or paclitaxel or buffer (control). Reduction of body surface and increased survival rates were assessed as therapeutic success. Survival of mice in all treatment groups was significantly enhanced when compared to the non-treatment control group. The combination of paclitaxel plus bevacizumab significantly improved body surface as well as overall survival in comparison to a treatment with only one of the drugs. Treatment of malignant effusion with a single dose of bevacizumab as an intraperitoneal application, with or without cytostatic co-medication, may be a powerful alternative to systemic treatment.

View Figures

View References

1	Eitan R, Levine DA, Abu-Rustum N, et al: The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer. 103:1397–1401. 2005. View Article : Google Scholar : PubMed/NCBI
2	Sherer DM, Eliakim R and Abulafia O: The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female. Gynecol Obstet Invest. 50:217–224. 2000. View Article : Google Scholar : PubMed/NCBI
3	Markman M: Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 4:277–283. 2003. View Article : Google Scholar : PubMed/NCBI
4	Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C and Atanackovic D: Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist. 14:1242–1251. 2009. View Article : Google Scholar : PubMed/NCBI
5	Aslam N and Marino CR: Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 161:2733–2737. 2001. View Article : Google Scholar : PubMed/NCBI
6	Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:983–985. 1983. View Article : Google Scholar
7	Huynh H, Teo CC and Soo KC: Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol Cancer Ther. 6:2959–2966. 2007. View Article : Google Scholar : PubMed/NCBI
8	Sack U, Hoffmann M, Zhao XJ, et al: Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J. 25:600–604. 2005. View Article : Google Scholar : PubMed/NCBI
9	Numnum TM, Rocconi RP, Whitworth J and Barnes MN: The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 102:425–428. 2006. View Article : Google Scholar : PubMed/NCBI
10	Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 25:5180–5186. 2007. View Article : Google Scholar
11	Simpkins F, Belinson JL and Rose PG: Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol. 107:118–123. 2007. View Article : Google Scholar
12	Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH and Rose GS: Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 111:530–532. 2008. View Article : Google Scholar : PubMed/NCBI
13	Burger RA, Sill MW, Monk BJ, Greer BE and Sorosky JI: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 25:5165–5171. 2007. View Article : Google Scholar : PubMed/NCBI
14	Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB and Ellis LM: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 6:373–378. 1999. View Article : Google Scholar : PubMed/NCBI
15	Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 25:581–611. 2004. View Article : Google Scholar : PubMed/NCBI
16	Rein DT, Breidenbach M, Nettelbeck DM, et al: Evaluation of tissue-specific promoters in carcinomas of the cervix uteri. J Gene Med. 6:1281–1289. 2004. View Article : Google Scholar : PubMed/NCBI
17	Gerber HP and Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65:671–680. 2005.PubMed/NCBI
18	Jain RK, Duda DG, Clark JW and Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 3:24–40. 2006. View Article : Google Scholar : PubMed/NCBI
19	Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T and Jaffe RB: Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol. 161:1917–1924. 2002. View Article : Google Scholar
20	Mabuchi S, Terai Y, Morishige K, et al: Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res. 14:7781–7789. 2008. View Article : Google Scholar : PubMed/NCBI
21	Shah DK, Shin BS, Veith J, Toth K, Bernacki RJ and Balthasar JP: Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. J Pharmacol Exp Ther. 329:580–591. 2009. View Article : Google Scholar : PubMed/NCBI
22	Davies S, Dai D, Pickett G, Thiel KW, Korovkina VP and Leslie KK: Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance. Oncol Rep. 25:855–862
23	Shah DK, Veith J, Bernacki RJ and Balthasar JP: Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer. Cancer Chemother Pharmacol. 68:951–958. 2011. View Article : Google Scholar : PubMed/NCBI